Funding opportunity for NSW-led projects in Non-Animal Technologies. Expressions of Interest are now open for the 2025 NAT-Net Research Pillar Competitive Grant Scheme.
Image credit: Retinal Organoid generated from human induced pluripotent stem cells. Source: Dr Anai Gonzalez Cordero, Stem Cell Medicine Group.
This grant supports collaborative, NSW-led research projects that drive groundbreaking discoveries and innovations in non-animal technologies -such as advanced in vitro models, computational methods, and biochemical assays – to improve medical research and reduce reliance on animal use.
𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲
Up to three grants of $200,000 each, for two-year projects commencing March 2026. Total funding pool: $600,000.
The University of New South Wales is the administering organisation of NAT-Net, with funding made possible by NSW Health.
𝗘𝗹𝗶𝗴𝗶𝗯𝗶𝗹𝗶𝘁𝘆
Collaborations must involve at least 𝘁𝘄𝗼 𝗲𝗹𝗶𝗴𝗶𝗯𝗹𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 (including at least one in NSW) and an early-mid career researcher (EMCR) as Chief Investigator. Projects must demonstrate substantial innovation in non-animal technologies. Host organisations may submit a maximum of two applications each.
𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗼𝗰𝗲𝘀𝘀
The application and selection process includes two stages;
• Stage 1 – Expression of Interest: 𝗼𝗽𝗲𝗻𝘀 𝗼𝗻 𝟮𝟴 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟱, and closes 25 August, 12PM AEST.
• Stage 2 – Full Application: short-listed Expressions of Interest will be invited to complete a Full Application from 10 October 2025.
A briefing session for applicants will be held:
🗓 Wednesday 13 August
🕛 12–1pm AEST
For full eligibility criteria, guidelines, and application forms, visit:
Access Guidelines hereInterested in Non-Animal modelling infrastructure and expertise?
Check below Phenomics Australia nodes and contact details:
Phenomics Australia Node | Capability | Contact 1 | Contact 2 |
High Throughput Screening | |||
High Throughput Screening | |||
In vitro genome engineering and disease modelling | |||
In vitro genome engineering and disease modelling | |||
In vitro genome engineering and disease modelling | |||
Translational Cancer Research Program (Harry Perkins Institute of Medical Research) | In vitro genome engineering and disease modelling | ||
High Throughput Screening | |||
High Throughput Screening | |||
Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | In vitro genome engineering and disease modelling | ||
In vitro genome engineering and disease modelling | |||
Biobanking and in vitro and in vivo genome engineering and disease modelling | |||
In vitro genome engineering and disease modelling |
